![]() |
市场调查报告书
商品编码
1820085
淋巴瘤治疗市场报告(按类型、检测类型、药物和地区)2025-2033Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2025-2033 |
2024年,全球淋巴瘤治疗市场规模达143亿美元。展望未来, IMARC Group预计到2033年,该市场规模将达到274亿美元,2025-2033年期间的复合年增长率(CAGR)为7.13%。治疗方式的不断进步、淋巴瘤发病率的上升、医疗支出的激增以及持续的技术创新是推动市场成长的主要因素。
淋巴瘤盛行率上升
由于人口老化和诊断能力提高等因素,淋巴瘤(包括霍奇金淋巴瘤和非霍奇金淋巴瘤)的发生率在全球范围内呈上升趋势。例如,根据美国癌症协会的数据,到2024年,将有近8万人罹患非何杰金氏淋巴瘤。这进一步推动了对高效治疗的需求,预计将在未来几年进一步推动淋巴瘤治疗市场的发展。
个人化医疗日益受到关注
对个人化医疗的日益关注极大地推动了淋巴瘤治疗市场的成长。例如,根据IMARC的数据,全球精准医疗市场规模在2023年达到752亿美元。展望未来, IMARC Group预计到2032年,该市场规模将达到1,683亿美元,2024-2032年期间的复合年增长率(CAGR)为9.1%。淋巴瘤治疗中的个人化医疗涉及根据患者的个别特征(包括基因、分子和免疫学特征)来客製化治疗方案。这些因素进一步对淋巴瘤治疗市场预测产生了正面影响。
增加研发投入
製药公司和研究机构在研发方面的大量投入推动了新型和改良淋巴瘤疗法的开发,并透过创新疗法扩大了市场。例如,2023年11月,白血病和淋巴瘤协会(LLS)——一家致力于血液癌症研究的私人资助机构——向七个国家的78个研究团队提供了6500万美元的新奖励。此外,正在进行的临床试验和研究也促进了治疗方案的改进和新型疗法的上市,从而提升了淋巴瘤治疗市场的收入。
The global lymphoma treatment market size reached USD 14.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The rising advancements in treatment modalities, increasing incidence of lymphoma, surging healthcare expenditure, and ongoing technological innovations are primarily driving the market's growth.
Rising Prevalence of Lymphoma
The prevalence of lymphoma, including both Hodgkin and non-Hodgkin lymphoma, is rising globally due to factors like aging populations and improved diagnostic capabilities. For instance, according to the American Cancer Society, nearly 80,000 people will suffer from non-Hodgkin lymphoma in 2024. This further drives the demand for efficient treatment, further expected to propel the lymphoma treatment market in the coming years.
Surging Focus on Personalized Medicine
The rising focus on personalized medicine is significantly driving growth in the lymphoma treatment market. For instance, according to IMARC, the global precision medicine market size reached US$ 75.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 168.3 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032. Personalized medicine in lymphoma treatment involves tailoring therapies based on individual patient characteristics, including genetic, molecular, and immunological profiles. These factors further positively influence the lymphoma treatment market forecast.
Increasing R&D Investments
Significant investments in R&D by pharmaceutical companies and research institutions drive the development of new and improved lymphoma treatments, expanding the market with innovative therapies. For instance, in November 2023, the Leukemia & Lymphoma Society (LLS), a private supporter of blood cancer research, granted $65 million in new awards to 78 research teams in seven countries. Moreover, ongoing clinical trials and research studies contribute to the advancement of treatment options and the introduction of novel therapies to the market, thereby boosting the lymphoma treatment market revenue.
According to the lymphoma treatment market outlook, Hodgkin lymphoma comprises a smaller proportion of all lymphomas, accounting for approximately 10% of cases worldwide. Moreover, it is more prevalent in developed countries compared to developing regions. Moreover, non-Hodgkin lymphoma is more common than Hodgkin lymphoma, accounting for approximately 90% of all lymphoma cases globally. NHL incidence rates have been increasing over the past few decades.
According to the lymphoma treatment market overview, chemotherapy involves the use of drugs to kill cancer cells or slow their growth. These drugs can be administered orally or intravenously and work by targeting rapidly dividing cells throughout the body. Moreover, radiation therapy uses high-energy beams to target and destroy cancer cells. It is often delivered externally (external beam radiation) or internally (brachytherapy). Apart from this, immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Key approaches include monoclonal antibodies and immune checkpoint inhibitors.
Adcetris is primarily used for the treatment of Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphoma (NHL), such as systemic anaplastic large cell lymphoma (sALCL). Moreover, Rituxan is a monoclonal antibody targeting CD20 antigen primarily used in B-cell NHL and certain autoimmune diseases like rheumatoid arthritis. Apart from this, Opdivo is an immune checkpoint inhibitor targeting PD-1 receptor used in various cancers, including melanoma, lung cancer, and Hodgkin lymphoma.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
According to the lymphoma treatment market statistics, North America represents a significant portion of the global lymphoma treatment market owing to the higher prevalence of lymphoma, particularly non-Hodgkin lymphoma (NHL), due to factors like aging population and environmental exposures. Moreover, the increasing emphasis on genomic profiling and targeted therapies, is driving the market growth in Europe. Apart from this, the rising incidence of lymphoma in Asia Pacific, partly due to aging populations, urbanization, and changing lifestyles is supporting the industry's demand.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: